DESTINY-PANTUMOUR04
Recruiting
Observational Study
Adenocarcinoma (NOS)
Anal Cancer
Bladder Cancer
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Gall Bladder Cancer
Gastrointestinal Stromal Tumour
Head and Neck Cancer
Liver Cancer
Melanoma
Mouth Cancer
Nasopharangeal Cancer
Neuroendocrine, Gastrointestinal Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cell Carcinoma
Salivary Gland Cancer
Sarcoma
Small Cell Lung Cancer
Testicular Cancer
Throat Cancer
Thyroid Cancer
Urethral Cancer
Vaginal Cancer
Vulvar Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 130
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- AstraZeneca · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Adults aged ≥18 years
2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the I…
Contacts
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
CONTACT